Clinical Trial Update: Trabectedin for Recurrent Grade II/III Meningioma [Phase 2]

View source ↗

Summary

Phase 2 trial of trabectedin for recurrent grade II/III meningioma has been completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningioma

Drugs mentioned

• Trabectedin (trabectedin)

Snippet

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC | Conditions: Recurrent High Grade Meningioma | Phase 2 | Status: COMPLETED | Results posted: 2025-07-10